BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 21239164)

  • 1. Reducing sample sizes in two-stage phase II cancer trials by using continuous tumour shrinkage end-points.
    Wason JM; Mander AP; Eisen TG
    Eur J Cancer; 2011 May; 47(7):983-9. PubMed ID: 21239164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.
    Karrison TG; Maitland ML; Stadler WM; Ratain MJ
    J Natl Cancer Inst; 2007 Oct; 99(19):1455-61. PubMed ID: 17895472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimising the design of phase II oncology trials: the importance of randomisation.
    Ratain MJ; Sargent DJ
    Eur J Cancer; 2009 Jan; 45(2):275-80. PubMed ID: 19059773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal adaptive two-stage designs for phase II cancer clinical trials.
    Englert S; Kieser M
    Biom J; 2013 Nov; 55(6):955-68. PubMed ID: 23868324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of error rates in single-arm versus randomized phase II cancer clinical trials.
    Tang H; Foster NR; Grothey A; Ansell SM; Goldberg RM; Sargent DJ
    J Clin Oncol; 2010 Apr; 28(11):1936-41. PubMed ID: 20212253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of a misspecification of response rates on type I and type II errors, in a phase II Simon design.
    Baey C; Le Deley MC
    Eur J Cancer; 2011 Jul; 47(11):1647-52. PubMed ID: 21493059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm Phase II design.
    Taylor JM; Braun TM; Li Z
    Clin Trials; 2006; 3(4):335-48. PubMed ID: 17060208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance of adaptive designs for single-armed phase II oncology trials.
    Kieser M; Englert S
    J Biopharm Stat; 2015; 25(3):602-15. PubMed ID: 24905363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adaptive two-stage designs in phase II clinical trials.
    Banerjee A; Tsiatis AA
    Stat Med; 2006 Oct; 25(19):3382-95. PubMed ID: 16479547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early selection in a randomized phase II clinical trial.
    Steinberg SM; Venzon DJ
    Stat Med; 2002 Jun; 21(12):1711-26. PubMed ID: 12111907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal two-stage randomized phase II clinical trials.
    Logan BR
    Clin Trials; 2005; 2(1):5-12. PubMed ID: 16279574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statistical issues for design and analysis of single-arm multi-stage phase II cancer clinical trials.
    Jung SH
    Contemp Clin Trials; 2015 May; 42():9-17. PubMed ID: 25749311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Operating characteristics of a Simon two-stage phase II clinical trial design incorporating continuous toxicity monitoring.
    Ray HE; Rai SN
    Pharm Stat; 2012; 11(2):170-6. PubMed ID: 22232063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A flexible multi-stage design for phase II oncology trials.
    Tan MT; Xiong X
    Pharm Stat; 2011; 10(4):369-73. PubMed ID: 22328328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative evaluation of single-arm versus randomized phase II cancer clinical trials.
    Pond GR; Abbasi S
    Clin Trials; 2011 Jun; 8(3):260-9. PubMed ID: 21511687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sample size tables for exact single-stage phase II designs.
    A'Hern RP
    Stat Med; 2001 Mar; 20(6):859-66. PubMed ID: 11252008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exact two-stage designs for phase II activity trials with rank-based endpoints.
    Wilding GE; Shan G; Hutson AD
    Contemp Clin Trials; 2012 Mar; 33(2):332-41. PubMed ID: 22074983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Curtailed two-stage designs with two dependent binary endpoints.
    Chen CM; Chi Y
    Pharm Stat; 2012; 11(1):57-62. PubMed ID: 22162348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group.
    Stone AM; Bushnell W; Denne J; Sargent DJ; Amit O; Chen C; Bailey-Iacona R; Helterbrand J; Williams G;
    Eur J Cancer; 2011 Aug; 47(12):1763-71. PubMed ID: 21435858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trials powered to detect tumor subtypes.
    Roberts JD; Ramakrishnan V
    Clin Cancer Res; 2011 Sep; 17(17):5538-45. PubMed ID: 21737510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.